October 4, 2018 Bio/Pharma/CRO PR/Corporate

Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018

Basel, 04 October 2018 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 Baloxavir marboxil – a first-in-class, single-dose, investigational oral medicine – is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable... Read more

September 24, 2018 Bio/Pharma/CRO

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid

Basel, 24 September 2018 Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic testing and so may benefit from FoundationOne Liquid FoundationOne Liquid... Read more

September 21, 2018 Bio/Pharma/CRO

CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis

Basel, 21 September 2018 CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous... Read more

September 21, 2018 Bio/Pharma/CRO

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia

Basel, 21 September 2018 Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Positive CHMP recommendation based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by... Read more

September 18, 2018 Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Reminder: Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer

Basel, 18 September 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event: Key data for Roche’s lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer Agenda Roche lung cancer portfolio key data IMpower133: Primary PFS, OS, and Safety in a Ph1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in... Read more

September 18, 2018 Clinical Research/Diagn.

Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases

Basel, 18 September 2018 Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases Roche launches an app ecosystem with the first two clinical decision support apps The apps query globally-renowned resources based on real-world data Patient-specific results lead to more personalised treatment decisions by oncology care teams Roche (SIX:... Read more

September 13, 2018 Acad, Gov/Utilities Microscopy

FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis

Basel, 13 September 2018 FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active... Read more

September 13, 2018 Bio/Pharma/CRO

Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running

Basel, 13 September 2018 Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running Sustainability is an integral part of Roche’s business strategy The company performed particularly well in Marketing Practices, Environmental and Social Reporting and Health Outcome Contribution For the tenth consecutive year, Roche (SIX: RO,... Read more